# LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering

Study · id `cardio:ct-nct06865885` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06865885](<https://clinicaltrials.gov/study/NCT06865885>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06865885

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT06865885. Randomized; no masking; primary purpose treatment. Start 2025-04-02 (actual); primary completion 2028-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT06865885, source copy `cardio:ctgov-nct06865885-2026-11-10`, retrieved 2026-11-18)
- Started: 2025-04-02 (actual) (ClinicalTrials.gov record NCT06865885, source copy `cardio:ctgov-nct06865885-2026-11-10`, retrieved 2026-11-18)
- Primary completion: 2028-06-01 (anticipated) (ClinicalTrials.gov record NCT06865885, source copy `cardio:ctgov-nct06865885-2026-11-10`, retrieved 2026-11-18)
- Completion: 2028-09-01 (anticipated) (ClinicalTrials.gov record NCT06865885, source copy `cardio:ctgov-nct06865885-2026-11-10`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT06865885, source copy `cardio:ctgov-nct06865885-2026-11-10`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06865885-2026-11-10`, retrieved 2026-11-18)

## The registry's words

- Brief title: LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering
- Acronym: SOLVE-LDL-C
- Condition: Drug Interactions
- Condition: Primary Prevention
- Condition: Cardiometabolic Syndrome
- Condition: LDL-Cholersterol Lowering
- Condition: Polypharmacy
- Intervention (Drug): Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Lead sponsor: University of California, San Diego
- Lead sponsor class: OTHER
- Collaborator: Novartis
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Metabolic syndrome (`cardio:metabolic-syndrome`)
- Registry lists this organization as the lead sponsor: University of California, San Diego (`cardio:org-university-of-california-san-diego`)
- Registry lists this organization as a collaborator: Novartis (`cardio:novartis`)

## Provenance

Content hash: cb2af4e86dd4741fca81d5c467e0f1ec14dacf635667591cf120573a5a00b08f
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
